CHILD syndrome. Phenotypic dichotomy in eicosanoid metabolism and proliferative rates among cultured dermal fibroblasts.
Dermal fibroblasts from a patient with CHILD syndrome (an acronym for congenital hemidysplasia with ichthyosiform erythroderma and limb defects) were obtained and successfully maintained in culture. Fibroblasts from an area of chronically hyperkeratotic skin were compared with fibroblasts from the corresponding contralateral area of normal skin in regard to proliferative activity and to both unstimulated and stimulated generation of PGE2, an eicosanoid with documented effects on both epidermal cell and fibroblast function. Compared with the uninvolved skin fibroblasts, those from involved skin showed (a) a slower rate of proliferation, (b) a cyclical pattern of PGE2 synthesis, and (c) an approximately 20-fold greater synthesis of PGE2 in response to human purified IL-1, a cytokine known to be secreted by epidermal keratinocytes. Furthermore, we were able to demonstrate that the cyclical generation of PGE2 by the involved skin fibroblasts is responsible for their slower rate of growth when compared with the uninvolved skin fibroblasts. These data document a phenotypic dichotomy between the uninvolved and involved skin fibroblasts in CHILD syndrome that may be exploited to increase our understanding of the nature of dermal influences that may affect epidermal growth and differentiation.
Goldyne
M E
ME
Department of Dermatology, Veterans Administration Medical Center, San Francisco, California 94121.
Williams
M L
ML
D000015:Abnormalities, Multiple / Q000378:metabolism*; D004247:DNA / Q000235:genetics / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism*; D004476:Ectodermal Dysplasia / Q000378:metabolism; D005347:Fibroblasts; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D017880:Limb Deformities, Congenital; D010641:Phenotype; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D013577:Syndrome
D004247:DNA; D015232:Dinoprostone; D007213:Indomethacin